Cingulate

Cingulate's Precision Timed Release (PTR) platform layers the same active stimulant molecule into a single tablet with multiple, precisely timed release profiles. The goal is a true once-daily dose that maintains therapeutic plasma levels through the entire active day and into the evening, without the sharp peaks and troughs associated with standard extended-release generics. The company has also engineered the formulations with physical and chemical barriers intended to deter common routes of abuse.

Investment decisions are made by the board of directors, led by Chairman and CEO Shane J. Schaffer, who founded the company. Schaffer owns a significant portion of the equity, and his operational control is augmented by board members like John Roberts, who has decades of CNS drug development experience, most notably from leading Durata Therapeutics through an FDA approval and acquisition. The executive team is small, making capital allocation highly centralized.

The methylphenidate and amphetamine molecules themselves are long off-patent. Cingulate's protection does not come from composition-of-matter patents on the drugs but from its formulation and delivery patents, which extend into the mid-2030s. The commercial moat, if the firm succeeds, will be built on FDA-approved labeling that claims a specific clinical benefit tied to the flat pharmacokinetic profile, making it harder for physicians to substitute a standard generic.

As of its last reported period, Cingulate had raised bridge capital intended to fund operations into the second quarter of 2025. It is a pre-revenue company burning cash on Phase 3 clinical trials. A failure to raise additional capital or secure a partnership before the cash runway expires—or a negative Phase 3 readout—would threaten its status as a going concern.

No. Cingulate is a single-purpose, publicly traded pharmaceutical development company. It has no affiliated philanthropic foundation, no family-office parent entity, and no known separate investment vehicles or club memberships. Its capital comes from public equity markets and institutional healthcare investors.

Cingulate does not source candidates externally or make fund commitments. The entire pipeline is built on internal, reformulated generics using its PTR platform. The company does not operate as an investment manager and holds no portfolio of external biotech equity stakes.

ADHD is a large, established market with well-understood regulatory pathways, allowing Cingulate to pursue 505(b)(2) applications that rely on existing safety data for the active ingredients, thereby lowering development risk and cost. While the lead assets target ADHD, the preclinical asset CTx-2103 (buspirone) signals an intention to apply the PTR platform to the broader anxiety and CNS market, provided the company survives to fund those later-stage trials.